首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation
【24h】

Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation

机译:同种异体干细胞移植后长期存活者的晚期死亡率和死亡原因

获取原文
获取原文并翻译 | 示例
       

摘要

We sought to assess the late mortality risks and causes of death among long-term survivors of allogeneic hematopoietic stem cell transplantation (HCT). The cases of 11,047 relapse-free survivors of a first HCT at least 2 years after HCT were analyzed. Standardized mortality ratios (SMR) were calculated and specific causes of death were compared with those of the Japanese population. Among relapse-free survivors at 2 years, overall survival percentages at 10 and 15 years were 87% and 83%, respectively. The overall risk of mortality was significantly higher compared with that of the general population. The risk of mortality was significantly higher from infection (SMR = 57.0), new hematologic malignancies (SMR = 2.2), other new malignancies (SMR = 3.0), respiratory causes (SMR = 109.3), gastrointestinal causes (SMR = 3.8), liver dysfunction (SMR = 6.1), genitourinary dysfunction (SMR = 17.6), and external or accidental causes (SMR = 23). The overall annual mortality rate showed a steep decrease from 2 to 5 years after HCT; however, the decrease rate slowed after 10 years but was still higher than that of the general population at 20 years after HCT. SMRs in the earlier period of 2 to 4 years after HCT and 5 years or longer after HCT were 16.1 and 7.4, respectively. Long-term survivors after allogeneic HCT are at higher risk of mortality from various causes other than the underlying disease that led to HCT. Screening and preventive measures should be given a central role in reducing the morbidity and mortality of Ha recipients on long-term follow-up. (C) 2016 American Society for Blood and Marrow Transplantation.
机译:我们试图评估异基因造血干细胞移植(HCT)的长期幸存者的晚期死亡风险和死亡原因。分析了HCT至少2年后第一个HCT的11,047名无复发幸存者的病例。计算标准死亡率(SMR),并将特定的死亡原因与日本人口的死亡原因进行比较。在2年无复发幸存者中,10年和15年的总生存率分别为87%和83%。与一般人群相比,总体的死亡风险要高得多。感染(SMR = 57.0),新的血液系统恶性肿瘤(SMR = 2.2),其他新的恶性肿瘤(SMR = 3.0),呼吸道原因(SMR = 109.3),胃肠道原因(SMR = 3.8),肝脏的死亡风险显着更高功能障碍(SMR = 6.1),泌尿生殖系统功能障碍(SMR = 17.6)和外部或意外原因(SMR = 23)。 HCT后2至5年,总的年度死亡率急剧下降;然而,降低的速度在10年后减慢,但仍高于HCT后20年的总人口下降速度。 HCT后2至4年和HCT后5年或更长时间的SMR分别为16.1和7.4。异基因HCT后长期存活者除导致HCT的潜在疾病外,还因各种原因导致更高的死亡风险。在长期随访中,筛查和预防措施应在降低Ha接受者的发病率和死亡率方面发挥中心作用。 (C)2016美国血液和骨髓移植学会。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号